Synergy IMT creates immunotherapeutics with more than one mechanism of activity to elicit more effective anti-tumor activity. 

Cloning antibodies from single B-cells and proprietary versatile modular platforms, are used to rapidly create and optimize multifunctional antibodies and other recombinant antigen binding formats.

Generating recombinant antibodies from single rabbit B-cells enables rapid identification of antibodies that bind to multiple species for efficacy and toxicity studies. The approach also facilitates the cloning of human antibodies from patient blood and the creation of safe, non-antigenic therapeutics.   

Modular platforms are used to generate and optimize novel combinations of immune cell agonists and/or immune checkpoint antagonists with enhanced tumor targeting and tumoricidal domains. Moreover, native ligands are incorporated into certain therapeutics to enhance activity by enabling a natural interface and tunable signaling through their target receptors.

Tumor targets include universal and selected tumor antigens.  Tumor cytotoxicity can be mediated initially by a cytotoxic moiety, eg an ADC, and ultimately through immune cell mechanisms targeting patient specific tumor antigens. Select combinations of specificities and valences are chosen to deliver safe and potent tumoricidal activity.  

Certain multifunctional therapeutics are designed to both eliminate tumor cells and to modify the composition of the tumor microenvironment to stimulate a synergistic and durable anti-tumor response beyond typical mono- and bispecific antibodies. 

To enhance efficacy and safety, certain monomeric therapeutics are engineered to be smaller than whole antibody bi- and tri-specifics for greater tumor penetrance, and to restrict their activity within a tumor microenvironment. 

Certain target proteins also function in the pathogenesis of neurodegenerative, viral, and fibrotic diseases.  Multispecific therapeutics are specifically tailored for treating these diseases.